Table 2. OS and RFS after liver resection in patients with HCC from studies that included PVTT and/or HVTT.
| Country/region | n/n | 1-year, % (95% CI) | P | n/n | 3-year, % (95% CI) | P | n/n | 5-year, % (95% CI) | P |
|---|---|---|---|---|---|---|---|---|---|
| OS* | |||||||||
| Global | 10/1,803 | 60.07 (49.22–70.00) | – | 10/1,803 | 27.34 (19.36–37.10) | – | 10/2,807 | 19.78 (13.85–27.44) | – |
| By country/region* | |||||||||
| China | 5/830 | 54.83 (41.60–67.41) | <0.0001 | 5/830 | 17.62** (15.17–20.36) | <0.0001 | 2/607 | 11.47* (9.16–14.25) | <0.0001 |
| Japan | 1/651 | 80.00 (76.75–82.90) | 1/651 | 56.60 (52.76–60.36) | 2/917 | 32.42 (19.01–49.51) | |||
| Taiwan | 0/0 | – | 0/0 | – | 1/76 | 15.70 (9.12–25.68) | |||
| France | 1/26 | 38.00 (21.73–57.50) | 1/26 | 20.00 (8.73–39.52) | 1/26 | 13.00 (4.55–31.91) | |||
| Italy | 1/62 | 53.30 (49.93–65.27) | 1/62 | 30.10 (20.02–42.56) | 1/62 | 20.00 (11.83–31.78) | |||
| Spain | 1/12 | 66.70 (37.62–86.93) | 1/12 | 33.30 (13.07–62.38) | 1/12 | 22.20 (6.81–52.68) | |||
| United States | 0/0 | – | 0/0 | – | 1/165 | 14.00 (9.49–20.17) | |||
| RFS* | |||||||||
| Global | 4/401 | 45.30 (38.00–52.79) | – | 4/401 | 20.88 (11.36–35.22) | – | 3/296 | 17.66 (13.72–22.42) | – |
| By country* | |||||||||
| China | 1/105 | 51.90 (42.39–61.27) | 0.03 | 1/105 | 7.90 (4.05–14.84) | 0.003 | 0/0 | – | 0.59 |
| Italy | 1/62 | 31.70 (21.37–44.21) | 1/62 | 20.80 (12.45–32.66) | 1/62 | 15.60 (8.52–26.85) | |||
| Spain | 1/12 | 58.30 (30.74–81.50) | 1/12 | 43.70 (19.88–70.83) | 1/12 | 21.90 (6.66–52.41) | |||
n/n, studies/patients; *, some studies encompassed multiple regions, so they were included in the global analysis but not in the regional/country analysis; **, all I2>89.2, all P value for available I2 were <0.05. OS, overall survival; RFS, recurrence free survival; HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; HVTT, hepatic vein tumor thrombosis.